文献速递艾滋病与性传播感染

抗逆转录病毒治疗期间低水平病毒血症和病毒短暂波动后的病毒学失败:欧洲多中心队列研究结果

Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort.
PubMed 文献 · Clin Infect Dis · 2023-01-01

研究基于EuResist整合数据库,纳入2005年或之后启动抗逆转录病毒治疗的HIV-1感染者,分析低水平病毒血症(LLV)和病毒短暂波动(blips)与后续病毒学失败(VF)的关联。结果显示,与病毒学抑制相比,blips和LLV均与VF风险升高相关,LLV期间有基因数据者中35%检出至少1个耐药突变。

要点

  • 与病毒学抑制相比,blips与病毒学失败风险升高相关(aHR 1.7,95%CI 1.3-2.2)。
  • 与病毒学抑制相比,LLV与病毒学失败风险升高相关(aHR 2.2,95%CI 1.6-3.0)。
  • LLV后90天内有基因数据者中,49/140(35%)检出至少1个耐药突变。

核心结论

  • 抗逆转录病毒治疗期间的blips和LLV均与后续病毒学失败风险升高相关。

研究设计与样本

  • 欧洲多中心队列研究,纳入EuResist整合数据库中2005年或之后启动抗逆转录病毒治疗的HIV-1感染者。
  • 共纳入22523名参与者,随访81837人年。
  • 暴露分组为病毒学抑制(≤50 copies/mL)、blips(单次VL 51-999 copies/mL)和LLV(重复VL 51-199 copies/mL),从ART启动后12个月开始分析。
  • 采用Cox比例风险模型,调整年龄、性别、注射吸毒、ART前VL、CD4计数、HIV-1亚型、ART类型和治疗经验。

主要发现

  • 随访期间共观察到1424例病毒学失败事件(VF,≥200 copies/mL)。
  • 与病毒学抑制相比,blips与VF风险升高相关(aHR 1.7;95%CI 1.3-2.2)。
  • 与病毒学抑制相比,LLV与VF风险升高相关(aHR 2.2;95%CI 1.6-3.0)。
  • 在限制于VL<200 copies/mL人群及2014年或之后启动ART者的亚组分析中,上述关联仍具有统计学显著性。
  • 在LLV后90天内有基因型数据者中,49/140(35%)检出至少1个耐药突变。

关键数值与推荐

  • LLV定义为重复可检测VL<200 copies/mL(具体为重复VL 51-199 copies/mL)。
  • blips定义为单次VL 51-999 copies/mL。
  • 病毒学失败定义为VL≥200 copies/mL。
  • blips与VF的aHR为1.7(95%CI 1.3-2.2)。
  • LLV与VF的aHR为2.2(95%CI 1.6-3.0)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unclear whether low-level viremia (LLV), defined as repeatedly detectable viral load (VL) of <200 copies/mL, and/or transient viremic episodes (blips) during antiretroviral therapy (ART), predict future virologic failure. We investigated the association between LLV, blips, and virologic failure (VF) in a multicenter European cohort. METHODS: People with HIV-1 who started ART in 2005 or later were identified from the EuResist Integrated Database. We analyzed the incidence of VF (≥200 copies/mL) depending on viremia exposure, starting 12 months after ART initiation (grouped as suppression [≤50 copies/mL], blips [isolated VL of 51-999 copies/mL], and LLV [repeated VLs of 51-199 copies/mL]) using Cox proportional hazard models adjusted for age, sex, injecting drug use, pre-ART VL, CD4 count, HIV-1 subtype, type of ART, and treatment experience. We queried the database for drug-resistance mutations (DRM) related to episodes of LLV and VF and compared those with baseline resistance data. RESULTS: During 81 837 person-years of follow-up, we observed 1424 events of VF in 22 523 participants. Both blips (adjusted subhazard ratio [aHR], 1.7; 95% confidence interval [CI], 1.3-2.2) and LLV (aHR, 2.2; 95% CI, 1.6-3.0) were associated with VF, compared with virologic suppression. These associations remained statistically significant in subanalyses restricted to people with VL <200 copies/mL and those starting ART 2014 or later. Among people with LLV and genotype data available within 90 days following LLV, 49/140 (35%) had at least 1 DRM. CONCLUSIONS: Both blips and LLV during ART are associated with increased risk of subsequent VF.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Elvstam O, Malmborn K, Elén S, et al. Virologic Failure Following Low-level Viremia and Viral Blips During Antiretroviral Therapy: Results From a European Multicenter Cohort. Clin Infect Dis. 2023. PMID: 36100984. doi:10.1093/cid/ciac762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。